文献速递心力衰竭与心肌病血脂与心血管预防

PCSK9-LDL受体轴与心力衰竭预后:BIOSTAT-CHF子分析

The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure: BIOSTAT-CHF Subanalysis.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

本研究基于BIOSTAT-CHF多中心前瞻性观察队列,纳入2174例心衰患者,分析PCSK9与LDLR水平对全因死亡及死亡/心衰住院复合终点的预测价值。结果显示PCSK9与死亡风险正相关,LDLR与死亡风险负相关,联合加入风险评分可改善预测效能。

要点

  • PCSK9水平升高与心衰患者全因死亡和复合终点风险独立正相关
  • LDLR水平升高与全因死亡风险负相关,与复合终点关联无统计学意义
  • 将PCSK9和LDLR纳入BIOSTAT-CHF风险评分可改善风险预测效能

核心结论

  • PCSK9-LDLR轴与心衰患者结局相关,PCSK9升高增加死亡风险,LDLR升高降低死亡风险。
  • 未来需研究PCSK9抑制能否改善心衰患者结局。

研究设计与样本

  • BIOSTAT-CHF为多中心、多国、前瞻性观察性研究,纳入心衰症状和/或体征加重的患者。
  • 共纳入2174例患者,平均年龄68±12岁,53.2%有缺血性心脏病史。
  • 主要终点为全因死亡和死亡或心衰非计划住院的复合终点。
  • 采用Cox比例风险回归分析PCSK9和LDLR同时校正后的效应,并加入已验证的BIOSTAT-CHF风险评分。

主要发现

  • 随访期间共569例死亡(26.2%),896例(41.2%)发生复合终点。
  • PCSK9中位数1.81 U/ml(IQR 1.45-2.18),LDLR中位数2.98 U/ml(IQR 2.45-3.53)。
  • 校正BIOSTAT-CHF风险评分、LDLR和他汀治疗后,PCSK9与死亡风险正相关(HR 1.24;95%CI 1.04-1.49;p=0.020)。
  • PCSK9与复合终点正相关(HR 1.21;95%CI 1.05-1.40;p=0.010)。
  • LDLR与死亡风险负相关(HR 0.86;95%CI 0.76-0.98;p=0.025),与复合终点关联无统计学意义(HR 0.92;95%CI 0.83-1.01;p=0.087)。

关键数值与推荐

  • PCSK9每升高1 U/ml,全因死亡风险HR 1.24(95%CI 1.04-1.49;p=0.020)。
  • PCSK9每升高1 U/ml,复合终点风险HR 1.21(95%CI 1.05-1.40;p=0.010)。
  • LDLR每升高1 U/ml,全因死亡风险HR 0.86(95%CI 0.76-0.98;p=0.025)。
  • LDLR每升高1 U/ml,复合终点风险HR 0.92(95%CI 0.83-1.01;p=0.087)。

临床怎么用

  • 在心衰患者中可考虑检测PCSK9和LDLR水平以辅助风险分层。
  • 将PCSK9和LDLR纳入现有BIOSTAT-CHF风险评分可能改善风险预测。
  • PCSK9抑制能否改善心衰结局尚需前瞻性研究验证,目前不能据此推荐治疗。

局限性

  • 本研究为观察性研究,不能确立因果关系。
  • PCSK9抑制对心衰结局的影响尚未评估,需未来研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds low-density lipoprotein receptor (LDLR), preventing its recycling. PCSK9 is a risk predictor and a biotarget in atherosclerosis progression. OBJECTIVES: The aim of this study was to determine whether the PCSK9-LDLR axis could predict risk in patients with heart failure (HF). METHODS: The BIOSTAT-CHF (Biology Study to Tailored Treatment in Chronic Heart Failure) is a multicenter, multinational, prospective, observational study that included patients with worsening HF signs and/or symptoms. The primary endpoints were all-cause mortality and the composite of mortality or unscheduled hospitalizations for HF. We implemented Cox proportional hazard regression to determine the simultaneously adjusted effect of PCSK9 and LDLR on both outcomes when added to the previously validated BIOSTAT-CHF risk scores. RESULTS: This study included 2,174 patients (mean age: 68 ± 12 years; 53.2% had a history of ischemic heart disease). Median (interquartile range) PCSK9 and LDLR levels were 1.81 U/ml (1.45 to 2.18) and 2.98 U/ml (2.45 to 3.53), respectively. During follow-up, 569 deaths (26.2%) and 896 (41.2%) composite endpoints were ascertained. A multivariable analysis, which included BIOSTAT-CHF risk scores, LDLR, and statin treatment as covariates, revealed a positive linear association between PCSK9 levels and the risk of mortality (hazard ratio [HR]: 1.24; 95% confidence interval [CI]: 1.04 to 1.49; p = 0.020) and the composite endpoint (HR: 1.21; 95% CI: 1.05 to 1.40; p = 0.010). A similar analysis for LDLR revealed a negative association with mortality (HR: 0.86; 95% CI: 0.76 to 0.98; p = 0.025) and the composite endpoint (HR: 0.92; 95% CI: 0.83 to 1.01; p = 0.087). Including PCSK9 and LDLR improved risk score performance. CONCLUSIONS: The PCSK9-LDLR axis was associated with outcomes in patients with HF. Future studies must assess whether PCSK9 inhibition will result in better outcomes in HF.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Bayes-Genis A, Núñez J, Zannad F, et al. The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure: BIOSTAT-CHF Subanalysis. J Am Coll Cardiol. 2017. PMID: 29050560. doi:10.1016/j.jacc.2017.08.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。